1. Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
   Weigang Xiu et al, 2021, Front. Oncol. CrossRef
2. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
   Lei Zhu et al, 2021, Cancer Res CrossRef
3. Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations
   Giuseppe Pelosi et al, 2021, JTO Clinical and Research Reports CrossRef
4. Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
   Ji Young Park et al, 2022, Tuberc Respir Dis CrossRef
5. Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
   Giulia Pasello et al, 2022, Front. Oncol. CrossRef
6. Acquired resistance mechanisms to osimertinib: the constant battle
   Ziad Zalaquett et al, 2023, Cancer Treatment Reviews CrossRef
7. MYC expression and Fatty acid oxidation in EGFR-TKI acquired resistance
   GuoSheng Wang et al, 2023, Drug Resistance Updates CrossRef
8. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
   Gee-Chen Chang et al, 2024, PLoS ONE CrossRef